IPO pricing is imminent; watch for final pricing and first-day trading. Positive phase 2a data reduces clinical risk for OD-001 but does not guarantee pivotal trial success. Monitor initiation of phase 2b monotherapy and phase 2a combination trials expected in H2 2026.
Executive Summary
Odyssey Therapeutics, a clinical-stage biopharma focused on autoimmune/inflammatory diseases, filed a revised S-1/A for its IPO, setting the offering at 13.24M shares (plus greenshoe) at $16-$18, with a concurrent $25M private placement. Positive phase 2a data for lead candidate OD-001 in ulcerative colitis provides a key value driver, but the company is pre-revenue, has substantial losses ($148.6M in 2025), and a going concern qualification.
Key Financial Metrics
Key Facts
- Offering 13,240,000 shares at $16-$18 per share; expected net proceeds ~$205.2M (IPO) plus ~$23.3M from concurrent private placement.
- Concurrent private placement of 1,470,588 shares at IPO price to TPG Orazio II (affiliate of existing stockholder).
- Positive topline phase 2a data for OD-001 (RIPK2 inhibitor) in ulcerative colitis: 27% clinical remission, 33% endoscopic improvement, well tolerated.
- Cash position $216.6M (Dec 2025); pro forma as-adjusted cash $445.0M; expected runway into H2 2028.
- Net loss of $148.6M in 2025 (vs $129.3M in 2024); accumulated deficit $568.1M.
- Management has expressed substantial doubt about going concern absent IPO proceeds.
Financial Impact
IPO net proceeds of ~$205M plus private placement net ~$23M provide funding into H2 2028; $135M allocated to OD-001 clinical development, $50M to SLC15A4 program.
Risk Factors
- Pre-revenue; no approved products; history of losses and going concern.
- Clinical trial risks: OD-001 still in early-stage; OD-002 in IND-enabling; failure in later trials would impair value.
- Substantial dilution: existing shareholders' ownership decreases; new investors pay $17 (midpoint) vs pro forma NAV of $9.54.
- Competition from approved biologics/small molecules in IBD and lupus; many larger players.
- Need for additional capital beyond H2 2028 to complete development and commercialization.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-202398 |
| Document: odtx-ex10_2.htm | 0001193125-26-202398 |
| Document: odtx-ex3_1.htm | 0001193125-26-202398 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $18.99 $19.00 | ▲ +0.05% | ▼ −0.47% | $19.30 (+1.63%) |
Aug 4, 2026 11w ago | 8-K | $19.96 $20.89 | ▲ +4.66% | ▲ +4.86% | $19.30 (−3.31%) |
Jun 17, 2026 18w ago | 8-K | $19.07 $18.72 | ▼ −1.84% | ▼ −1.52% | $19.30 (+1.21%) |
May 11, 2026 24w ago | Insider Cluster | $17.45 $17.90 | ▲ +2.58% | ▲ +2.72% | $19.30 (+10.60%) |
May 8, 2026 24w ago | 424B4 | $17.45 $17.90 | ▲ +2.58% | ▲ +2.72% | $19.30 (+10.60%) |
May 8, 2026 24w ago | EFFECT | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers